Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease

Obesity

Volumn 25, Issue 1, 2017, Pages 94-101

  Zelber Sagi, Shira ^a,b   Azar, Shahar ^c   Nemirovski, Alina ^c   Webb, Muriel ^a,d   Halpern, Zamir ^a,d   Shibolet, Oren ^a,d   Tam, Joseph ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ALANINE AMINOTRANSFERASE; ANANDAMIDE; ARACHIDONIC ACID; GLUCOSE; INSULIN; TRIACYLGLYCEROL; URIC ACID; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOCANNABINOID BLOOD LEVEL; FEMALE; GENDER; HEPATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; RENOGRAPHY; SCREENING; TANDEM MASS SPECTROMETRY; TREND STUDY; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; ALANINE TRANSAMINASE; ARACHIDONIC ACIDS; CASE-CONTROL STUDIES; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYUNSATURATED ALKAMIDES; WAIST CIRCUMFERENCE;

EID: 85006040091     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21687     Document Type: Article

References (40)

1. van den Berghe G. The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J Inherit Metab Dis 1991;14:407–420.
2. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011;53:346–355.
3. Howlett AC. Cannabinoid receptor signaling. Handbk Exp Pharmacol 2005;168:53–79.
4. Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171:31–38.
5. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298–1305.
6. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010;59:926–934.
7. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742–755.
8. Floreani A, Lazzari R, Macchi V, et al. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. J Gastroenterol 2010;45:68–76.
9. Siegmund SV, Qian T, de Minicis S, et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007;21:2798–2806.
10. Auguet T, Berlanga A, Guiu-Jurado E, et al. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. BioMed Res Int 2014;2014:502542. doi: 10.1155/2014/502542.
11. Liu J, Zhou L, Xiong K, et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142:1218–1228.
12. Abdulnour J, Yasari S, Rabasa-Lhoret R, et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obesity 2014;22:211–216.
13. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053–3060.
14. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007;31:692–699.
15. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838–2843.
16. Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014;20:4382–4392.
17. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012;56:1145–1151.
18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023.
19. Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009;192:909–914.
20. Jeong WI, Osei-Hyiaman D, Park O, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:227–235.
21. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity 2009;17:1696–1701.
22. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160–3169.
23. Jourdan T, Demizieux L, Gresti J, et al. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants. Hepatology 2012;55:790–799.
24. Di Marzo V, Cote M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52:213–217.
25. Westerbacka J, Kotronen A, Fielding BA, et al. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology 2010;139:1961–1971. e1961.
26. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282–284.
27. Hollister LE, Reaven GM. Delta-9-tetrahydrocannabinol and glucose tolerance. Clin Pharmacol Ther 1974;16:297–302.
28. Di Marzo V, Verrijken A, Hakkarainen A, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009;161:715–722.
29. Patsenker E, Sachse P, Chicca A, et al. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci 2015;16:7057–7076.
30. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822–825.
31. Alvheim AR, Malde MK, Osei-Hyiaman D, et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity 2012;20:1984–1994.
32. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 2001;98:6402–6406.
33. Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008;1781:52–60.
34. Demizieux L, Piscitelli F, Troy-Fioramonti S, et al. Early low-fat diet enriched with linolenic acid reduces liver endocannabinoid tone and improves late glycemic control after a high-fat diet challenge in mice. Diabetes 2016;65:1824–1837.
35. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14:1347–1356.
36. Steffen BT, Steffen LM, Tracy R, et al. Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis. Int J Obes 2012;36:797–804.
37. Liu TW, Heden TD, Matthew Morris E, Fritsche KL, Vieira-Potter VJ, Thyfault JP. High-fat diet alters serum fatty acid profiles in obesity prone rats: implications for in vitro studies. Lipids 2015;50:997–1008.
38. Caraceni P, Viola A, Piscitelli F, et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 2010;30:816–825.
39. Fernandez-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004;24:477–483.
40. Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009;58:1724–1730.